Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home | Suppliers

ARTES Biotechnology - Contract R&D Services and Patent Protected Expression Systems for Recombinant Proteins

ARTES Biotechnology offers contract R&D services with innovative solutions for recombinant strain development in microbial expression systems.

ARTES provides technology and know-how for the establishment of reliable and competitive processes, used for e.g. the production of innovative targets that are applied in the life science industry, for fine chemicals or as biobetters.

ARTES focuses on protein production from the yeasts Hansenula polymorpha and Arxula adeninivorans. These platform technologies are secured by exclusive licenses as well as additional components like the chaperone technology (ultimate tool to improve secretion) or the Xplor® Vector System (tool for evaluation and screening of yeast).

ARTES' team has more than 20 years experience in commercial project management in contract research, in gene expression trouble-shooting and in the set-up of manufacturing processes. Altogether this has resulted in marketed products approved amongst others by the US-FDA.

ARTES' services include:

  • Production of stable integrants
  • Optimisation of expression strains
  • Genomic characterisation of production strains
  • Optimisation of protein secretion
  • Optimisation of culture conditions
  • Fermentation development
  • Downstream processing
  • Protein analytics
  • Project management
  • Tech-transfer

ARTES offers tailor-made studies for the generation of recombinant production strains to provide the most efficient solution.

Technology platforms

The need for suitable expression systems for the highly efficient and reliable production of pharmaceutical and industrial proteins is increasing continuously due to ever-growing new and generic target proteins. The selection of an appropriate and economic expression system is a crucial decision during any development. To assist in this process ARTES offers customer tailored studies and services. Please see the product tab to see the services.

Track record

  • Pharmaceutical and feed/food products registered worldwide
  • Biosimilars marketed include Hepatitis B vaccines, Insulin, Interferon alpha 2a and Hirudin
  • Industrial enzymes approved by US-FDA a.o.
  • GRAS confirmation for several products achieved

Elisabeth-Selbert-Str. 9
40764 Langenfeld, Germany

Tel: +49 (0) 2173 27587-0
Fax: +49 (0) 2173 27587-77
www.artes-biotechnology.com